Estrogen receptor antagonist 2 manufacturers
- Camizestrant
-
- $150.00
-
2026-08-15
- CAS:2222844-89-3
- Purity: 99.90%
- Supply Ability: 10g
- Camizestrant
-
- $150.00
-
2026-07-27
- CAS:2222844-89-3
- Purity: 99.90%
- Supply Ability: 10g
|
| | Estrogen receptor antagonist 2 Basic information |
| Product Name: | Estrogen receptor antagonist 2 | | Synonyms: | Estrogen receptor antagonist 2;N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine;3-Pyridinamine, N-[1-(3-fluoropropyl)-3-azetidinyl]-6-[(6S,8R)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3H-pyrazolo[4,3-f]isoquinolin-6-yl]-;Camizestrant (AZD-9833);Camizestrant, 10 mM in DMSO;Unii-jup57A8epz;Camizestrant,2222844-89-3,Pharmaceutical Chemicals;AZD-9833 | | CAS: | 2222844-89-3 | | MF: | C24H28F4N6 | | MW: | 476.51 | | EINECS: | | | Product Categories: | | | Mol File: | 2222844-89-3.mol |  |
| | Estrogen receptor antagonist 2 Chemical Properties |
| Boiling point | 590.2±50.0 °C(Predicted) | | density | 1.318±0.06 g/cm3(Predicted) | | pka | 14.25±0.60(Predicted) | | form | Solid | | color | Off-white to light yellow | | InChIKey | WDHOIABIERMLGY-CMJOXMDJSA-N | | SMILES | C1=NC([C@@H]2C3=C(C4C=NNC=4C=C3)C[C@@H](C)N2CC(F)(F)F)=CC=C1NC1CN(CCCF)C1 |
| | Estrogen receptor antagonist 2 Usage And Synthesis |
| Uses | Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER+ HER2-advanced breast cancer[1]. | | in vivo | Camizestrant (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft[1].
Camizestrant (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice[1]. | Animal Model: | Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells in female NSG mice[1] | | Dosage: | 0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg | | Administration: | Oral administration; 30 days; once daily | | Result: | Inhibited tumor growth in a dose-dependent manner. |
| | References | [1] Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931. |
| | Estrogen receptor antagonist 2 Preparation Products And Raw materials |
|